Probiodrug - Spotlight on Abeta MAbs after Biogen’s data

The surprise announcement of the disease-modifying effect obtained by Biogen and Eisai with their MAb BAN2401 in a Phase II trial announced during presentations this summer and autumn may reignite interest in the amyloid theory and in the Alzheimer’s disease (AD) field in general. With its own positive peer-reviewed Phase IIa data published, Probiodrug is now preparing the Phase IIb programme. Near-term focus is to continue engaging with potential licensing partners, raise funds and start enrolling patients. Our valuation is €270m or €32.9/share.